Olaparib Tablets Production Approval

Release date: 2024-07-10 15:24:14     Article From: Lucius Laos     Recommended: 165

10L1028_23 奥拉帕利 批文_00.jpg

Olaparib Tablets is a PARP (polymerase associated adenosine diphosphate ribose polymerase) inhibitor. Its indications include ovarian cancer, breast cancer, pancreatic cancer, prostate cancer and other malignant tumors. It is a first-line treatment drug for breast cancer and first-line maintenance treatment drug for ovarian cancer recommended by NCCN clinical guidelines.

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.

Contact US

Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos

E-mail:laoslucius@gmail.com

Whatsapp:

ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved